We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy.
Ophthalmology 1994 January
BACKGROUND: In high-risk keratoplasty, the failure rate from rejection is high, especially in the early postoperative period. If rejection could be prevented during this period, then ultimately a degree of immunologic privilege may be re-established, resulting in long-term graft survival. Cyclosporine (CSA) given systemically prevents graft rejection, but because of the potential side effects and cost, the duration of treatment is an important factor. The author examines the effectiveness of short- and long-term CSA regimens in preventing irreversible graft rejection.
METHODS: Forty-three patients with high-risk corneas (vascularization in 3 or 4 quadrants and > 16 stromal vessels) received corneal grafts and systemic CSA. Fourteen patients received the drug for 12 months and 29 for a shorter period of 4 to 6 months. A similar high-risk group of 37 patients received no systemic medication.
RESULTS: In the control group, 23 grafts (62.2%) irreversibly rejected, compared with 9 (31.0%) and 1 (7.1%) in the short- and long-term CSA groups, respectively. The grafts of patients receiving CSA had a significantly better survival rate (P = 0.0005) than those in the control group. If time of CSA treatment also was considered, significance increased (P = 0.00008).
CONCLUSIONS: Systemic CSA significantly reduces failure from irreversible rejection in high-risk keratoplasty, but for maximal effect, a 12-month period of treatment is necessary.
METHODS: Forty-three patients with high-risk corneas (vascularization in 3 or 4 quadrants and > 16 stromal vessels) received corneal grafts and systemic CSA. Fourteen patients received the drug for 12 months and 29 for a shorter period of 4 to 6 months. A similar high-risk group of 37 patients received no systemic medication.
RESULTS: In the control group, 23 grafts (62.2%) irreversibly rejected, compared with 9 (31.0%) and 1 (7.1%) in the short- and long-term CSA groups, respectively. The grafts of patients receiving CSA had a significantly better survival rate (P = 0.0005) than those in the control group. If time of CSA treatment also was considered, significance increased (P = 0.00008).
CONCLUSIONS: Systemic CSA significantly reduces failure from irreversible rejection in high-risk keratoplasty, but for maximal effect, a 12-month period of treatment is necessary.
Full text links
Related Resources
Trending Papers
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Revascularization Strategy in Myocardial Infarction with Multivessel Disease.Journal of Clinical Medicine 2024 March 27
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app